Novartis: Kidney Neoplasms trials

The registry lists 10 Kidney Neoplasms studies with Novartis as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 4Phase 2 5Phase 3 1Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor TreatmentCompletedNCT03200717Phase 2Results posted
• Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02460224Phase 1/2Results posted
• Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell CarcinomaTerminatedNCT01545817Phase 2Results posted
• Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or PazopanibCompletedNCT01514448Phase 4Results posted
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00903175Phase 2Results posted
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or SunitinibCompletedNCT00410124Phase 3Results posted
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02947165Phase 1
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedNCT02077933Phase 1
• EPO906 Therapy in Patients With Advanced Kidney CancerCompletedNCT00035243Phase 2